A Phase I Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations

Trial Profile

A Phase I Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 07 May 2018

At a glance

  • Drugs IDH 305 (Primary)
  • Indications Acute myeloid leukaemia; Cancer; Glioma; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Sponsors Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 30 Apr 2018 Planned End Date changed from 26 Dec 2018 to 17 Apr 2019.
    • 30 Apr 2018 Planned primary completion date changed from 2 Feb 2018 to 17 Apr 2019.
    • 30 Apr 2018 Status changed from suspended to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top